An irreversible A1-selective adenosine agonist preconditions rabbit heart

Area of Science:

• Cardiology
• Pharmacology
• Physiology

Background:

• Ischemic preconditioning (IP) protects the heart from ischemia-reperfusion injury.
• The precise mechanisms underlying IP remain incompletely understood.
• Adenosine receptors, particularly the A1 subtype, are implicated in IP.

Purpose of the Study:

• To investigate if an irreversible agonist of the A1 adenosine receptor, m-DITC ADAC, can replicate the protective effects of ischemic preconditioning in the rabbit heart.
• To determine if targeting the A1 adenosine receptor with an irreversible agonist could offer a novel therapeutic strategy for myocardial protection.

Main Methods:

• Isolated Krebs buffer-perfused rabbit hearts subjected to regional ischemia and reperfusion.
• Infarct size determination using tetrazolium staining.
• Administration of A1 adenosine receptor agonists (CCPA, m-DITC ADAC) and antagonist (DPCPX) to assess protective effects.

Main Results:

• Ischemic preconditioning reduced infarct size significantly (9 +/- 2% vs. 32 +/- 2% in controls).
• The A1-selective agonist CCPA mimicked preconditioning (13 +/- 7% infarction), with protection blocked by DPCPX.
• The irreversible agonist m-DITC ADAC also provided significant protection (15 +/- 4% infarction).

Conclusions:

• m-DITC ADAC effectively mimics the protective effects of ischemic preconditioning in the rabbit heart.
• Irreversible stimulation of the A1 adenosine receptor represents a novel approach for achieving prolonged cardioprotection.
• A single intracoronary injection of an irreversible agonist may offer an extended window of protection against cardiac injury.